ImClone Continues Talks for Sale: Report
ImClone Systems (IMCL) is expected to announce Monday that it is continuing talks to sell itself to a major pharmaceutical company for about $6.1 billion, according to people familiar with the matter, the Wall Street Journal reports.
TheStreet.com BioTalk: IMCL, BMY
Icahn reiterated to Bristol-Myers Chairman James Cornelius that a large, unnamed pharmaceutical company has bid $70 a share, subject to due diligence until Sept. 28.The Journal reports ImClone is expected to announce a deadline Monday by which it hopes to have a deal with its other suitor. The two sides remain in "deep discussions" and believe they can reach a resolution within days. ImClone is best known for its Erbitux cancer drug, Bristol-Myers sells ImClone's Erbitux cancer treatment in the U.S. ImClone hasn't identified the company it has been holding talks with but speculation has swirled around Pfizer (PFE), the Journal reports. Eli Lilly (LLY) also has been named as a possible suitor. Shares of ImClone closed Friday at $63.38.
Select the service that is right for you!COMPARE ALL SERVICES
- $2.5+ million portfolio
- Large-cap and dividend focus
- Intraday trade alerts from Cramer
- Weekly roundups
Access the tool that DOMINATES the Russell 2000 and the S&P 500.
- Buy, hold, or sell recommendations for over 4,300 stocks
- Unlimited research reports on your favorite stocks
- A custom stock screener
- Upgrade/downgrade alerts
- Diversified model portfolio of dividend stocks
- Alerts when market news affect the portfolio
- Bi-weekly updates with exact steps to take - BUY, HOLD, SELL
- Real Money + Doug Kass Plus 15 more Wall Street Pros
- Intraday commentary & news
- Ultra-actionable trading ideas
- 100+ monthly options trading ideas
- Actionable options commentary & news
- Real-time trading community
- Options TV